1. Regeneron starting late stage trials of coronavirus drug cocktail — Bristol-Myers pays Dragonfly Therapeutics $55M to bring NK cells to neuro diseases — JNJ in $480M-plus deal with Emergent for coronavirus vaccine supply — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Obagi

Discussion in 'SkinMedica' started by Anonymous, Mar 20, 2013 at 3:34 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Oh boy! Did you guys see that Valeant bought our competitor Obagi Oh boy! Oh boy! They're all gonna lose their jobs and we can steal all of their business! Oh boy! Oh boy! Cant wait to see this line of emails about how many more hours of my week and week end will have to spent putting together some dumbass special promotion to try to useat Obagi products. Oh sure! Because Obagi and Valeant just got together to let the business die out and I guess they needed to waste that 340 million bucks right? I think we better use any time spent on this keeping are very close eye on what they do now to not only keep what they have, but to grow to what they must have. Get ready....if you think this is good news, you don't the first thing about Valeant.
     

  2. Anonymous

    Anonymous Guest

    Please tell us about Valeant...seems like you know it all.
     
  3. Anonymous

    Anonymous Guest

    Valeant + Obagi > Allergan + SkinMedica

    Not all SM people will lose job but about 40% of you will.
     
  4. Anonymous

    Anonymous Guest

    We should raise price along with Obagi. We can beat them in sales and don't need a price advantage to do so! Raise it!
     
  5. Anonymous

    Anonymous Guest

    The Obagi layoffs are not unexpected but still not a good sign for our market in general. The savings that can be gained by streamlining operations of the Obagi line is a model Allergan will at least have to look at. Allergan is no Valeant but they will be watching to see what Obagi sales do with a more efficient structure. No consideration of performance seems to be the norm these days. Where do we have too many bodies is main consideration. SM will have to cut back at some point too so don't think we are immune.
     
  6. Anonymous

    Anonymous Guest

    Nice try SM, but your "Obagi targeting" initiative is going to be a huge failure and will end up costing you tons of money in returns. Can you say backfire? Backlash?